Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management

The panel provides an overview of the various Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) treatment phases, highlighting the important discussion around inpatient versus outpatient care.

EP: 1.Overview of Characteristics Unique to Ph+ ALL

EP: 2.Timely Detection: Incidence and Prevalence of Ph+ ALL

EP: 3.Supporting Ph+ ALL Patient: Emotional Challenges and Quality of Life

EP: 4.Screening and Diagnosing of Ph+ ALL in Adults

Now Viewing

EP: 5.Diagnosis and Treatment Timeline: Different Phases of Ph+ ALL Management

EP: 6.Current Front-Line Targeted Treatments in Ph+ ALL

EP: 7.Prior Authorization and Access to Targeted Treatment for Ph+ ALL Patients

EP: 8.PhALLCON Trial: Efficacy and Safety of Ponatinib in Ph+ ALL Patients

EP: 9.Value-Based Care Models Optimizing Ph+ ALL Patient Care

EP: 10.Unmet Needs in Screening, Diagnosis, and Management of Ph+ ALL

EP: 11.Disparities in Access to Care for Ph+ ALL patients

EP: 12.The Future of Ph+ ALL Treatments

EP: 13.Concluding Thoughts on Ph+ ALL Treatment

Related Videos

Related Content

Advertisement

July 26th 2024

Meta-Analysis Finds Link Between Ankylosing Spondylitis, Cancer Risk

Rose McNulty

The authors of the new meta-analysis aimed to provide an update on the association between ankylosing spondylitis and cancer incidence.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

July 25th 2024

ARTISTRY-1: Simplifying HIV Treatment for the Most Complex Cases

Maggie L. Shaw

These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

July 25th 2024

Atezolizumab for NSCLC Safe and Effective Before and After CRT

Julia Bonavitacola

Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.

July 25th 2024

Dual-Target CAR T Cells Achieve 100% Response Rate in MM

Maggie L. Shaw

This new analysis examined the investigational chimeric antigen receptor (CAR) T-cell therapy GC012F among patients with newly diagnosed and high-risk multiple myeloma (MM).

Related Content

Advertisement

July 26th 2024

Meta-Analysis Finds Link Between Ankylosing Spondylitis, Cancer Risk

Rose McNulty

The authors of the new meta-analysis aimed to provide an update on the association between ankylosing spondylitis and cancer incidence.

July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.

July 25th 2024

ARTISTRY-1: Simplifying HIV Treatment for the Most Complex Cases

Maggie L. Shaw

These 48-week data from ARTISTRY-1 build on 24-week results previously presented and show enduring efficacy of bictegravir plus lenacapavir.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

July 25th 2024

Atezolizumab for NSCLC Safe and Effective Before and After CRT

Julia Bonavitacola

Patients with unresectable stage III non–small cell lung cancer (NSCLC) who received atezolizumab before and after chemoradiation therapy (CRT) had both safe and effective results.

July 25th 2024

Dual-Target CAR T Cells Achieve 100% Response Rate in MM

Maggie L. Shaw

This new analysis examined the investigational chimeric antigen receptor (CAR) T-cell therapy GC012F among patients with newly diagnosed and high-risk multiple myeloma (MM).